[go: up one dir, main page]

CN1367692A - 烟碱转运系统 - Google Patents

烟碱转运系统 Download PDF

Info

Publication number
CN1367692A
CN1367692A CN00807470A CN00807470A CN1367692A CN 1367692 A CN1367692 A CN 1367692A CN 00807470 A CN00807470 A CN 00807470A CN 00807470 A CN00807470 A CN 00807470A CN 1367692 A CN1367692 A CN 1367692A
Authority
CN
China
Prior art keywords
nicotine
microcapsule
delivery systems
lozenge
encapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN00807470A
Other languages
English (en)
Other versions
CN1200711C (zh
Inventor
戴维·勒西利·麦克内特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FUID TECHNOLOGY Co Ltd
Original Assignee
FUID TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FUID TECHNOLOGY Co Ltd filed Critical FUID TECHNOLOGY Co Ltd
Publication of CN1367692A publication Critical patent/CN1367692A/zh
Application granted granted Critical
Publication of CN1200711C publication Critical patent/CN1200711C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明公开了烟碱转运系统,所述系统包含封装在微胶囊系统中的烟碱,所述微胶囊系统在与烟碱溶剂接触时释放所封装的烟碱。

Description

烟碱转运系统
本发明涉及烟碱转运系统。
烟碱通常在卷烟，主要是雪茄烟和烟丝(pipe tobacco)中，以吸烟的形式被吸收。在更小的范围内，烟草或其制品被咀嚼。如今，更少的是鼻吸入。吸烟已被宣布对健康有害，但是烟碱本身在适当的量，不象吸烟一样有害，吸烟的害处是因为卷烟的烟中烟碱以外的其它成分，烟碱本身在适当的量甚至可能是有益的—很多时候其被报道为辅助浓度(aiding concentration)。
虽然还有一些疑问，烟碱已被普遍认为确有成瘾性，提高对烟草的税、政府的健康警告、因吸烟而得绝症的人或其亲属对烟草公司的频繁诉讼，似乎都未减少其消费。
有几种商品化的帮助那些希望戒烟的人的产品。它们采用片剂、口香糖和药贴的形式，所有这些形式都试图避免烟及与之相关的致癌或其它有害成分的产生而转运烟碱。
配方这些产品的问题是烟碱本身是极易挥发的液体，其沸点在大气压下低至123℃-125℃，这将由于配方期间的蒸发损失以及为确保合理的保质期需要密封产品以防止烟碱蒸发而使将其混入产品中变得困难。与此同时，烟碱必须在使用时易于释放——在口香糖或锭剂的情况下在口中易于释放；或者在药贴的情况下易于通过皮肤释放。
烟碱注射的方式是通过溶解在脂肪组织中。烟碱不易在肠中被吸收，没有产品试图被用以吞服。
当然，药贴有一些临床价值，并且毫无疑问十分有效，然而药贴不美观。口香糖常常和抽烟一样被认为是反社会的—口香糖有许多其使用者忽略的处置问题，这导致其在新加坡是不合法的，很可能别的国家会效仿该措施。在所有的途径中，最美观的—不遗留任何需要处置的东西，可以吮吸而避免有时极令人反感的咀嚼运动的锭剂—可能是最难配方的，通常需要高温加工，导致通过蒸发的烟碱损失和锭剂中不确定的烟碱最终剂量，如果需要合理的保质期，还需要特殊保护以防终产物中的烟碱蒸发。
本发明提供避免已有技术问题的烟碱转运系统，其可以在已有范围内产生改善的产品，尤其是对于锭剂。
本发明包括烟碱转运系统，所述系统包含封装在微胶囊系统中的烟碱，所述微胶囊系统在与烟碱溶剂接触时释放所封装的烟碱。
被靶向的烟碱溶剂可以是口腔脂肪组织。
微胶囊可以是酵母细胞。该系统可以包含负载有烟碱的细胞和稀释用的空细胞的混合物。
该系统可以存在于固体载体中，为了受控转运，微胶囊从该载体表面被逐步释放。
固体载体可以包含在唾液中可溶或可分散的物质，且可以是锭剂，锭剂可以是糖基的。锭剂可以具有这样的大小、溶解性和烟碱的负载，它们使其在4至20分钟的使用时间里转运相当于一支卷烟所转运的剂量的烟碱。锭剂可以是长形的，长度在5至20厘米之间，且通过具有优先的折断位置，其可被折断成多个部分，各部分均能够舒适地被容纳在口中。
然而，该固体载体可以是口香糖。
该系统可以包含矫味物质，其也可以被封装在微胶囊系统中，也可以包含维生素添加物，其也可以被封装入微胶囊系统中。
该系统可以被包含在药贴中。
根据本发明的烟碱转运系统和包含其的产品的实施方案将参照
附图描述，其中：
图1是微胶囊化烟碱的制备方法的示意图；
图2是锭剂产品的一个实施方案的视图；
图3是锭剂产品的第二个实施方案的视图。
图1说明烟碱转运系统的制备方法，所述系统包含封装入微胶囊系统的烟碱，所述微胶囊系统在与烟碱溶剂接触时释放烟碱。
液态烟酸(nicotine acid)11形式的烟碱被倾入具有搅拌器13的混和容器12中。将定量的烟碱混入一定体积的酵母细胞14中，以给出烟碱进入各酵母细胞的合理浓度的吸收。合适的混和是25克烟碱、50克酵母细胞和100克水。将其在约40℃搅拌1-24小时。通过离心分离细胞并将细胞干燥。预期的负载是25-60％(重量)烟碱进入细胞，取决于所用的混和物。
在该方法的第二阶段，将这样的负载有烟碱的酵母细胞14从容器12中倾入大体积的酵母细胞中，此大体积的酵母细胞在第二个混和容器15中，容器15也具有搅拌器13，并搅拌混合物。
这样将得到封装在酵母细胞中的预期浓度的烟碱。
然后将该混和的负载酵母细胞和稀释剂酵母细胞混入具有适量酵母的产品中，以给出期望的产品中烟碱的剂量。
两个这种产品在图2和图3中说明。
图2说明锭形长条糖21，它可能有9或10厘米长以适于装入如同卖香烟时所用的包装中。长条21上具有横向的凹槽22，使其能被折断成一口体积(bite-size)的片。
图3说明类似的产品31，这次的形状更象卷烟，仍然有横向的凹槽32以供折断。图2和图3的外观在GB 2 299 756 A中首次提出。
这些产品都很象卷烟，它们可以被用作戒烟的辅助剂，或者在不允许吸烟的地方用作卷烟替代品，通过它们的负载的酵母含量，它们含有吸一支烟所转运的等量烟碱。
也可以加入矫味剂例如薄荷、苏格兰威士忌、法国科涅克白兰地酒或薄荷醇，同样以类似的方式封装入酵母中，也可以加入其它有益物质如维生素添加物。

Claims (16)

1.烟碱转运系统，所述系统包含封装在微胶囊系统中的烟碱，所述微胶囊系统在与烟碱溶剂接触时释放所封装的烟碱。
2.根据权利要求1的烟碱转运系统，其中烟碱溶剂是口腔脂肪组织。
3.根据权利要求1或2的烟碱转运系统，其中微胶囊是酵母细胞。
4.根据权利要求3的烟碱转运系统，其包含负载有烟碱的酵母细胞和稀释用的空细胞的混合物。
5.根据权利要求1至4中任一权利要求的烟碱转运系统，其存在于固体载体中，为了受控转运，微胶囊从该载体表面被逐步释放。
6.根据权利要求5的系统，其中固体载体包含在唾液中可溶或可分散的物质。
7.根据权利要求6的系统，其中固体载体是锭剂。
8.根据权利要求7的系统，其中锭剂是糖基的。
9.根据权利要求7或8的系统，其具有这样的大小、溶解性和烟碱的负载，它们使其在4至20分钟的使用时间里转运相当于一支卷烟所转运的量的烟碱。
10.根据权利要求9的系统，其中锭剂是长形的，长度在5至20厘米之间，且通过具有优先的折断位置，其可被折断成多个部分，各部分均能够舒适地被容纳在口中。
11.根据权利要求5的系统，其中固体载体是口香糖。
12.根据权利要求1至11中的任一权利要求的系统，其包含矫味物质。
13.根据权利要求23的系统，其中矫味物质也被封装在微胶囊系统中。
14.根据权利要求1至13中的任一权利要求的系统，其包含维生素添加物。
15.根据权利要求14的系统，其中维生素也被封装在微胶囊系统中。
16.根据权利要求1至4中任一权利要求的系统，其被包含在药贴中。
CNB008074704A 1999-05-13 2000-05-11 烟碱转运系统 Expired - Fee Related CN1200711C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9911037.1 1999-05-13
GBGB9911037.1A GB9911037D0 (en) 1999-05-13 1999-05-13 Nicotine delivery service

Publications (2)

Publication Number Publication Date
CN1367692A true CN1367692A (zh) 2002-09-04
CN1200711C CN1200711C (zh) 2005-05-11

Family

ID=10853329

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008074704A Expired - Fee Related CN1200711C (zh) 1999-05-13 2000-05-11 烟碱转运系统

Country Status (12)

Country Link
US (2) US20060120974A1 (zh)
EP (1) EP1176961B1 (zh)
JP (1) JP2002544230A (zh)
CN (1) CN1200711C (zh)
AT (1) ATE253363T1 (zh)
AU (1) AU4769900A (zh)
DE (1) DE60006376T2 (zh)
DK (1) DK1176961T3 (zh)
ES (1) ES2209882T3 (zh)
GB (1) GB9911037D0 (zh)
PT (1) PT1176961E (zh)
WO (1) WO2000069440A2 (zh)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076605A1 (de) * 2001-03-23 2002-10-03 Symrise Gmbh & Co. Kg Verfahren zur herstellung von einkapselungen
DE60235117D1 (de) † 2001-11-15 2010-03-04 San Ei Gen Ffi Inc Mikrokapseln und diese enthaltende oralpräparate
US20060127489A1 (en) * 2002-10-24 2006-06-15 Michael Crothers Targeted delivery
GB2395124A (en) * 2002-11-16 2004-05-19 Fluid Technologies Plc Palatable microcapsules
GB2406053B (en) * 2003-09-10 2008-08-20 Micap Plc Antimicrobial composition
PL3659437T3 (pl) 2004-01-23 2022-08-22 Eden Research Plc Sposoby zabijania nicieni obejmujące aplikację enkapsulowanego składnika terpenowego
GB2413563A (en) * 2004-04-27 2005-11-02 Micap Plc Composition comprising a biocide encapsulated within a fungal cell
AU2005234989A1 (en) * 2004-04-27 2005-11-03 Micap Plc Microbial encapsulation
GB2418654A (en) * 2004-09-29 2006-04-05 Micap Plc Microbial encapsulation
DK2338332T3 (da) 2004-05-20 2014-05-12 Eden Research Plc Hul glucanpartikel eller cellevægspartikel indkapslende en terpenkomponent
EP1954130B1 (en) 2005-11-30 2018-06-13 Eden Research Plc Methods comprising terpene mixtures comprising thymol and citral
WO2007063267A1 (en) 2005-11-30 2007-06-07 Eden Research Plc Terpene-containing compositions and methods of making and using them
USD613029S1 (en) 2007-11-20 2010-04-06 Mars, Incorporated Candy
AU2010204511B2 (en) 2009-01-19 2014-10-30 W. R. Grace & Co.-Conn. Introduction of mesoporosity in low Si/Al zeolites
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
GB201220940D0 (en) 2012-11-21 2013-01-02 Eden Research Plc Method P
US11503853B2 (en) 2013-09-09 2022-11-22 R.J. Reynolds Tobacco Company Smokeless tobacco composition incorporating a botanical material
US10357054B2 (en) 2013-10-16 2019-07-23 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
JP6745728B2 (ja) 2014-05-27 2020-08-26 アール・ジエイ・レイノルズ・タバコ・カンパニー ニコチン塩、共結晶、及び塩共結晶複合体
WO2016069740A1 (en) * 2014-10-29 2016-05-06 The Regents Of The University Of California Bioactive delivery vehicles
US10881133B2 (en) 2015-04-16 2021-01-05 R.J. Reynolds Tobacco Company Tobacco-derived cellulosic sugar
US10869497B2 (en) 2015-09-08 2020-12-22 R.J. Reynolds Tobacco Company High-pressure cold pasteurization of tobacco material
PL3379952T3 (pl) 2015-11-25 2024-03-18 R. J. Reynolds Tobacco Company Kompleksy soli, kokryształów i kokryształów soli nikotyny
US10532046B2 (en) 2015-12-03 2020-01-14 Niconovum Usa, Inc. Multi-phase delivery compositions and products incorporating such compositions
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
US10499684B2 (en) 2016-01-28 2019-12-10 R.J. Reynolds Tobacco Company Tobacco-derived flavorants
US11154087B2 (en) 2016-02-02 2021-10-26 R.J. Reynolds Tobacco Company Method for preparing flavorful compounds isolated from black liquor and products incorporating the flavorful compounds
US11091446B2 (en) 2017-03-24 2021-08-17 R.J. Reynolds Tobacco Company Methods of selectively forming substituted pyrazines
EP3681865A1 (en) 2017-09-05 2020-07-22 R. J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US20190307082A1 (en) 2018-04-05 2019-10-10 R.J. Reynolds Tobacco Company Oriental tobacco production methods
BR112020025604A2 (pt) 2018-06-15 2021-03-23 R.J. Reynolds Tobacco Company purificação de nicotina
USD920628S1 (en) 2019-11-26 2021-06-01 Canopy Growth Corporation Confectionery product
WO2021116865A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Agents for oral composition
WO2021116855A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral compositions and methods of manufacture
CA3211601A1 (en) 2021-03-09 2022-09-15 Jr. Darrell Eugene Holton Oral products and methods of manufacture
US20220354785A1 (en) 2021-04-22 2022-11-10 Nicoventures Trading Limited Oral lozenge products
US20220369688A1 (en) 2021-05-06 2022-11-24 Nicoventures Trading Limited Oral compositions and related methods for reducing throat irritation
CA3233375A1 (en) 2021-09-30 2023-04-06 Michael Zawadzki Oral product with a basic amine and an ion pairing agent
WO2023084499A1 (en) 2021-11-15 2023-05-19 Nicoventures Trading Limited Products with enhanced sensory characteristics
WO2023248187A1 (en) 2022-06-24 2023-12-28 Nicoventures Trading Limited Oral composition comprising a receptor modulator
WO2024074842A1 (en) 2022-10-07 2024-04-11 Nicoventures Trading Limited Oral product
GB202214803D0 (en) 2022-10-07 2022-11-23 Nicoventures Trading Ltd Oral product
GB202214771D0 (en) 2022-10-07 2022-11-23 Nicoventures Trading Ltd Oral product
GB202214775D0 (en) 2022-10-07 2022-11-23 Nicoventures Trading Ltd Oral product
WO2024074839A1 (en) 2022-10-07 2024-04-11 Nicoventures Trading Limited Oral product
WO2024074843A1 (en) 2022-10-07 2024-04-11 Nicoventures Trading Limited Oral product
WO2024095163A1 (en) 2022-11-01 2024-05-10 Nicoventures Trading Limited Oral composition comprising encapsulated ph adjusting agent
GB202216465D0 (en) 2022-11-04 2022-12-21 Nicoventures Trading Ltd Oral product
WO2024095011A1 (en) 2022-11-04 2024-05-10 Nicoventures Trading Limited Oral product
WO2024180481A1 (en) 2023-02-28 2024-09-06 Nicoventures Trading Limited Caffeine-containing oral product
GB202304445D0 (en) 2023-03-27 2023-05-10 Nicoventures Trading Ltd Oral product
GB202307278D0 (en) 2023-05-16 2023-06-28 Nicoventures Holdings Ltd Oral product
GB202307279D0 (en) 2023-05-16 2023-06-28 Nicoventures Trading Ltd Oral product

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8317576D0 (en) * 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
GB2299756A (en) * 1995-03-29 1996-10-16 Gilbert Falkingham Clayton Gelatinous pastille containing nicotine
ATE288255T1 (de) * 1996-04-12 2005-02-15 Novadel Pharma Inc Polares bukkales spray
US6358060B2 (en) * 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen

Also Published As

Publication number Publication date
CN1200711C (zh) 2005-05-11
EP1176961B1 (en) 2003-11-05
JP2002544230A (ja) 2002-12-24
DE60006376T2 (de) 2004-09-09
ES2209882T3 (es) 2004-07-01
PT1176961E (pt) 2004-03-31
WO2000069440A3 (en) 2001-04-05
US20070269417A1 (en) 2007-11-22
DE60006376D1 (de) 2003-12-11
ATE253363T1 (de) 2003-11-15
AU4769900A (en) 2000-12-05
WO2000069440A2 (en) 2000-11-23
EP1176961A2 (en) 2002-02-06
GB9911037D0 (en) 1999-07-14
US20060120974A1 (en) 2006-06-08
DK1176961T3 (da) 2004-03-15

Similar Documents

Publication Publication Date Title
CN1200711C (zh) 烟碱转运系统
EP0737065B1 (en) Process for preparing solid pharmaceutical dosage forms
US4835187A (en) Spray dried ibuprofen
US5827541A (en) Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
KR950013753B1 (ko) 분무 건조된 아세트아미노펜, 이의 제조방법 및 이를 함유하는 약제학적 제형
US5587180A (en) Process for making a particulate support matrix for making a rapidly dissolving tablet
US4616047A (en) Galenic form for oral administration and its method of preparation by lyophilization of an oil-in-water emulsion
US4835186A (en) Spray dried ibuprofen
US20020098198A1 (en) Oral drug delivery system
US5837287A (en) Process for preparing solid pharmaceutical dosage forms
EP0479005A1 (fr) Composition pharmaceutique sous forme de gel dans un emballage distributeur
EP0268383B1 (en) Spray dried acetaminophen
US4771077A (en) Spray dried acetaminophen
RU2161954C2 (ru) Быстрорастворяющиеся во рту лекарственные формы
WO2019030561A1 (en) COMPOSITION CONTAINING CANNABINOIDS HAVING ENHANCED BIOAVAILABILITY
JP2004321077A (ja) ラッカーゼ封入カプセルを含有するガム
JPH07501799A (ja) ジメチコンパステル類
EP1675604A1 (en) Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii)
JPS63130528A (ja) 親水性物質含有軟カプセル剤

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee